Goal-directed action is transiently impaired in an hAPP-J20 mouse model of Alzheimer's disease, and in aging male mice regardless of genotype
A. Dhungana, S. Becchi, J. Leake, G. Morris, N. Avgan, B. Balleine, B. Vissel, L. A. Bradfield
Abstract
Cognitive-behavioural testing in preclinical models of Alzheimers disease has typically been limited to visuo-spatial memory tests and has failed to capture the broad scope of deficits patients also display in goal-directed action control. The current study addresses this gap by providing the first comprehensive investigation of how goal-directed actions are affected in a transgenic mouse model of Alzheimers disease. Specifically, we tested outcome devaluation performance - a popular test of goal-directed action - in male and female human amyloid precursor protein (hAPP)-J20 mice. Mice were first trained to press a left and right lever for unique pellet and sucrose outcomes respectively (counterbalanced) over four days. On test, mice were fed one of the two outcomes to reduce its value via sensory specific satiety and subsequently given a choice between levers. Goal-directed action was intact for 36-week-old wildtype mice of both sexes, because they responded more on the lever associated with the still-valued outcome than that associated with the devalued outcome (i.e. Valued > Devalued). Goal-directed action was impaired (Valued = Devalued) for J20 mice of both sexes, and for 52-week-old male mice regardless of genotype. Following an additional 4 days of lever press training (i.e., 8 days lever pressing in total), outcome devaluation was intact for all mice regardless of age or genotype. Immunohistochemical analysis revealed that increased microglial expression in the dorsal CA1 region of the hippocampus was associated with poorer outcome devaluation performance on initial tests, but not with tests performed after 8 days of lever pressing. Together, these data demonstrate that goal-directed action is transiently impaired in J20 mice of both sexes and in aging male mice regardless of genotype, and that this impairment is related to neuroinflammation in the dorsal CA1 region of the hippocampus.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Time Course of Recognition Memory Impairment and Glial Pathology in the hApp-J20 Mouse Model of Alzheimer’s Disease
Kamar E. Ameen‐Ali, Julie E. Simpson, … Jason Berwick·Journal of Alzheimer s DiseasePeer-reviewed·Feb 19, 2019
- Revealing hidden knowledge in amnestic mice
Andrea Santi, Sharlen Moore, … Kishore V. Kuchibhotla·bioRxiv·Jan 9, 2025
- Progressive impairments in executive function in the APP/PS1 model of Alzheimer’s disease as measured by translatable touchscreen testing
A. Shepherd, J. K. H. Lim, … E. L. Burrows·bioRxiv·Aug 21, 2019
- Generation of a hybrid AppNL-G-F/NL-G-F xThy1-GCaMP6s+/- Alzheimer disease mouse mitigates the behavioral and hippocampal encoding deficits of APP knock-in mutations of AppNL-G-F/NL-G-F mice
Samsoon Inayat, Brendan B. McAllister, … Majid H. Mohajerani·bioRxiv·Nov 18, 2022
- Chemogenetic activation of midline thalamic nuclei fails to ameliorate memory deficits in two mouse models of Alzheimer's disease
Shivali Kohli, Lilya Andrianova, … Michael T. Craig·bioRxiv·Jun 30, 2021
- APP-KI mice do not display the hallmark age-dependent cognitive decline of amyloid diseases
Lisa Blackmer‐Raynolds, Lyndsey D. Lipson, … Timothy Robert Sampson·bioRxiv·May 24, 2024